|
|
|
|
| |
|
|
| Röhsig,L.M.; Damin,D.C.; Stefani,S.D.; Castro Jr.,C.G.; Roisenberg,I.; Schwartsmann,G.. |
| von Willebrand factor (vWF) is a protein that mediates platelet adherence to the subendothelium during primary hemostasis. High plasma vWF concentrations have been reported in patients with various types of cancer, such as head and neck, laryngeal and prostatic cancer, probably representing an acute phase reactant. In the present study we determined the plasma levels of vWF antigen (vWF:Ag) by quantitative immunoelectrophoresis in 128 female patients with breast cancer as well as in 47 women with benign breast disease and in 27 healthy female controls. The levels of vWF:Ag were 170.7 ± 78 U/dl in patients with cancer, 148.4 ± 59 U/dl in patients with benign disease and 130.6 ± 45 U/dl in controls (P<0.005). We also detected a significant increase in the... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Von Willebrand factor; Breast cancer; Malignancy. |
| Ano: 2001 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2001000900004 |
| |
|
| |
|
| |
|
| |
|
|
| Lopes,A.A.; Barreto,A.C.; Maeda,N.Y.; Cícero,C.; Soares,R.P.S.; Bydlowski,S.P.; Rich,S.. |
| Biomarkers have been identified for pulmonary arterial hypertension, but are less well defined for specific etiologies such as congenital heart disease-associated pulmonary arterial hypertension (CHDPAH). We measured plasma levels of eight microvascular dysfunction markers in CHDPAH, and tested for associations with survival. A cohort of 46 inoperable CHDPAH patients (age 15.0 to 60.2 years, median 33.5 years, female:male 29:17) was prospectively followed for 0.7 to 4.0 years (median 3.6 years). Plasma levels of von Willebrand factor antigen (VWF:Ag), tissue plasminogen activator (t-PA) and its inhibitor (PAI-1), P-selectin, reactive C-protein, tumor necrosis factor alpha, and interleukin-6 and -10 were measured at baseline, and at 30, 90, and 180 days in... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Pulmonary hypertension; Congenital heart disease; Eisenmenger syndrome; Endothelial dysfunction; Von Willebrand factor; Th2 cytokine response. |
| Ano: 2011 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011001200011 |
| |
|
|
| Barreto,A.C.; Maeda,N.Y.; Soares,R.P.S.; Cícero,C.; Lopes,A.A.. |
| We investigated whether chronic rosuvastatin administration could improve the abnormalities of the circulating levels of vascular dysfunction markers in pulmonary arterial hypertension (PAH). Sixty patients, aged 13 to 60 years, with idiopathic (N = 14) or congenital heart disease-associated PAH (N = 46) were equally but randomly assigned to rosuvastatin treatment (10 mg a day, orally) or placebo for 6 months in a blind fashion. Plasma levels of P-selectin, tissue-plasminogen activator and its inhibitor as well as von Willebrand factor antigen were measured by enzyme-linked immunoassay before and after 1, 3, and 6 months of treatment. Baseline levels of biomarkers were elevated (68, 16, 45 and 46% increase relative to controls, for P-selectin, von... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Pulmonary hypertension; Statins; Endothelial dysfunction; P-selectin; Tissue-plasminogen activator and inhibitor; Von Willebrand factor. |
| Ano: 2008 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000800003 |
| |
|
|
|
